abbv-154
mAbexperimentalADC
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 2, 2021 (NCT04888585)
Timeline
Indications
Mechanism of action
- TNF-alphaANTAGONIST
TNFA
Chemistry & pharmacology
- Payload
- GRM1
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05556226 | Phase 1 | Oct 18, 2022 | AbbVie |
| NCT05068284 | Phase 2 | Oct 28, 2021 | AbbVie |
| NCT04972968 | Phase 2 | Sep 9, 2021 | AbbVie |
| NCT04888585 | Phase 2 | Jun 2, 2021 | AbbVie |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1